Asset Publisher
Research, Maternal, Child and Reproductive Health

PROTECT

PReparing for Optimal Phase III/IV maTErnal Group B StreptococCal vaccine Trials in Africa

Duration
01/03/2024 - 01/03/2027
Coordinator
Azucena Bardají
Funded by
Co-funded by the European Union (EDCTP3)

Two vaccines designed for pregnant women to protect their unborn infant are entering late-phase development and will prevent infections from group B Streptococcus and respiratory syncytial virus, respectively. For these vaccines to be approved, they must work effectively without causing any unwanted responses. To implement these vaccines in countries with low resources, healthcare systems must be strengthened by improving vaccine safety monitoring and surveillance of infection and advancing vaccine delivery, vaccine confidence, and patient participation. The rapid rollout of electronic health records (EHR) in Kenya, Mozambique, Malawi, and Uganda offers an opportunity to use routine data to strengthen reporting of rates of adverse pregnancy, neonatal and infant outcomes, and any adverse events following immunisation; this will be imperative in informing and preparing for future large scale vaccination rollout campaigns.

Our approach will address key gaps in EHR to develop pregnancy registries embedded within national reporting systems to establish this data, including baseline rates of pregnancy and infancy outcomes for Tetanus and COVID-19 vaccines currently in use. These reporting systems will allow monitoring of potential safety signals once new vaccines are introduced. Experts in EHR, obstetrics and gynaecology, paediatrics, microbiology, clinical trials, and implementation research will develop the motivation and tools needed to monitor and evaluate current and future maternal vaccines.

We will work closely with the WHO, African Medicines Agency and country stakeholders, co-developing pregnancy registries, sentinel site microbiological surveillance systems, and maternal vaccination communications toolkits in preparation for the decade of maternal vaccines. Our programme of work culminates in a network of maternal vaccine trial sites that can rapidly evaluate vaccines in pregnancy from late-stage trials through to introduction on a national level.

 

Total Funding

4,322,509 €

Our Team

Coordinator

ISGlobal Team

Other projects

See Past Projects

CaDMIA-plus

Continued validation of the minimally invasive autopsy for the investigation of the causes of death in infants, and establishment of a research and training center to study causes of death

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

MIBio

Identification of Prematurity and Pre-Eclampsia as Causes of Mortality

MULTIPLY

MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention

MA-CoV

Prevalence and impact of SARS-CoV-2 infection on maternal and infant health in African populations

IPERVAC-SL

Impact of perceptions of COVID-19 vaccines on health-seeking behaviours in Sierra Leone

RESPIRE

Respiratory syncytial virus (RSV) in African pregnant women and children

VITAL

Towards preparedness for new maternal vaccinations: Understanding barriers and facilitators to maternal vaccine acceptance

HIV drug resistance (HIVDR)

Description of HIV drug resistance patterns and its association with the risk of HIV mother to child transmission among pregnant women from southern Mozambique